The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Official Title: A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation
Study ID: NCT05194995
Brief Summary: This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer,advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.
Detailed Description: The primary objective of this study is to evaluate the safety and tolerability of JAB-21822 in combination with cetuximab to determine the MTD and RP2D during Dose Escalation phase; then to evaluate preliminary antitumor activity when JAB-21822 is administered in combination with cetuximab during Dose Expansion phase in patients with advanced colorectal cancer,advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research site31, Beijing, Beijing, China
Research site01, Beijing, Beijing, China
Research site02, Beijing, Beijing, China
Research site12, Beijing, Beijing, China
Research site20, Xiamen, Fujian, China
Research site26, Foshan, Guangdong, China
Research site03, Guangzhou, Guangdong, China
Research site13, Nanning, Guangxi, China
Research site06, Harbin, Heilongjiang, China
Research site05, Zhengzhou, Henan, China
Research site07, Zhengzhou, Henan, China
Research site18, Wuhan, Hubei, China
Research site11, Changsha, Hunan, China
Research site29, Changsha, Hunan, China
Research site09, Nanjing, Jiangsu, China
Research site24, Nanjing, Jiangsu, China
Research site32, Nanjing, Jiangsu, China
Research site08, Nanchang, Jiangxi, China
Research site04, Changchun, Jilin, China
Research site10, Shenyang, Liaoning, China
Research site14, Yinchuan, Ningxia, China
Research site15, Jinan, Shandong, China
Research site16, Linyi, Shandong, China
Research site28, Shanghai, Shanghai, China
Research site22, Xi'an, Shanxi, China
Research site23, Xi'an, Shanxi, China
Research site17, Chengdu, Sichuan, China
Research site19, Hangzhou, Zhejiang, China
Research site21, Hangzhou, Zhejiang, China
Name: Jacobio Pharmaceuticals
Affiliation: Jacobio Pharmaceuticals
Role: STUDY_DIRECTOR